Canopy Growth Corp
Canopy Growth Corporation (CGC)
Overview
Canopy Growth Corporation is a cannabis producer and distributor headquartered in Smiths Falls, Ontario, dual-listed on the Toronto Stock Exchange (WEED) and Nasdaq Global Select Market (CGC), which requires it to file a Form 10-K rather than the 20-F used by most Canadian foreign private issuers. For fiscal year 2026 (ended March 31, 2026), the company reported roughly $284.6 million CAD in revenue, up about 5.8% year over year, and employed approximately 1,128 people. In U.S.-dollar terms, trailing-twelve-month revenue was about $206.8 million, up 6.8%, but the company remains deeply unprofitable, posting a net loss of roughly $163.8 million on a trailing basis, and its market capitalization has collapsed to about $392.6 million with shares trading under $1. The company disclosed material weaknesses in internal controls related to warrant accounting, requiring restatement of financial statements spanning fiscal 2024 through fiscal 2026, underscoring the operational and financial turbulence that has characterized Canopy since Canadian cannabis legalization gave way to years of oversupply and price compression.
What They Do & How They Make Money
Canopy makes money by cultivating, manufacturing, and selling cannabis products - dried flower, pre-rolled joints, extracts, oils, softgel capsules, edibles, beverages, and vapes - to medical and adult-use customers in Canada, plus medical cannabis sales in Germany, Poland, and Australia, and vaporizer device sales globally through its Storz & Bickel subsidiary. Its Canadian adult-use business runs through cultivation and manufacturing facilities in Ontario and Quebec (including its flagship Smiths Falls facility), selling through provincial cannabis control authorities, while its medical business operates through Spectrum Therapeutics, Abba Medix, Apollo, and Canada House Clinics. Rather than directly operating in the U.S. federally illegal cannabis market, Canopy holds a non-controlling equity investment in Canopy USA, a separate entity structured to give Canopy indirect economic exposure to U.S. cannabis assets (including former acquisition targets like Acreage and Wana) while remaining compliant with Nasdaq listing rules and federal law.
Business Segments
Canopy does not break out formal reporting segments in the traditional multi-division sense but operates across distinct product and geographic lines:
- Canadian Cannabis (Medical & Adult-Use) - The core business, encompassing cultivation, manufacturing, and sale of dried flower, pre-rolls, extracts, and edibles under brands including Tweed, 7ACRES, DOJA, Deep Space, and medical brands Spectrum Therapeutics and Canada House.
- International Medical Cannabis - Medical cannabis sales in Germany and Poland and medical/device sales in Australia.
- Storz & Bickel - German-manufactured premium vaporizer devices sold globally, one of the more stable, higher-margin pieces of the portfolio.
- Canopy USA (equity-method investment) - Indirect exposure to U.S. multi-state cannabis operators and brands, positioning Canopy for potential upside if U.S. federal cannabis policy changes.
Competitors
Canopy competes against other large Canadian licensed producers (Tilray, Aurora Cannabis, Organigram), U.S. multi-state operators active in cannabis-friendly states, and, in the medical and consumer wellness space, more diversified pharmaceutical and CPG competitors. In vaporizers, Storz & Bickel competes against other premium and mass-market device makers. The Canadian adult-use cannabis market remains highly fragmented and price-competitive following years of oversupply, compressing margins across the industry.
Competitive Position
Canopy's competitive position has weakened substantially since its early years as the best-capitalized, highest-profile name in legal cannabis; years of oversupply-driven price compression in the Canadian market, heavy cash burn, and now a disclosed material weakness in internal controls have eroded both its financial standing and investor confidence, reflected in a market cap under $400 million and a sub-$1 share price. Its remaining strengths are real: recognizable consumer brands (Tweed, 7ACRES), a differentiated medical cannabis platform (Spectrum Therapeutics), the higher-margin Storz & Bickel vaporizer business, and a structurally creative (if still unproven) path to U.S. cannabis exposure through Canopy USA ahead of potential federal rescheduling or legalization. The industry itself offers limited structural moat - cannabis cultivation is increasingly commoditized, provincial control-board distribution limits producers' pricing power, and brand loyalty in a heavily regulated, price-sensitive market is harder to build than in typical consumer categories. Canopy's path forward depends on stabilizing its balance sheet (it raised over $374 million through at-the-market offerings and secured a $150 million term loan in fiscal 2026), remediating its internal-control weaknesses, and successfully positioning Canopy USA to capture value if U.S. cannabis policy loosens.